Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.

about

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Renal Toxicities of Targeted Therapies.Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.

P2860

Q26749324-64D915F8-75EE-45B5-8F2E-D692A7BAB1B6 Q38448007-2323A8D1-26C2-4778-962C-384317184052 Q49188770-4D10A463-B593-4759-90A9-4BD43D82EAB1

P2860

Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.

Item

http://www.wikidata.org/entity/Q40229471

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Simultaneous manifestation of ...... with dasatinib: a case report.

@en

type

Item

label

Simultaneous manifestation of ...... with dasatinib: a case report.

@en

prefLabel

Simultaneous manifestation of ...... with dasatinib: a case report.

@en

P1476

Simultaneous manifestation of ...... with dasatinib: a case report

@en

P2093

A Giannouli

http://www.w3.org/2001/XMLSchema#string

C Savopoulos

http://www.w3.org/2001/XMLSchema#string

G Kaiafa

http://www.w3.org/2001/XMLSchema#string

N Kakaletsis

http://www.w3.org/2001/XMLSchema#string

N Papadopoulos

http://www.w3.org/2001/XMLSchema#string

S Zisekas

http://www.w3.org/2001/XMLSchema#string

P2860

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo

Role of platelet-derived growth factors in physiology and medicine

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

New dosing schedules of dasatinib for CML and adverse event management

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.

Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.

P304

102-105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCPT.12107

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Apostolos I. Hatzitolios

V Perifanis

P577

2013-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258280335

http://www.w3.org/2001/XMLSchema#string

P698

24188312

http://www.w3.org/2001/XMLSchema#string

Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.

about

P2860

P2860

Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698